Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis

被引：0
|
作者：
Krueger, J. G. [1 ]
Garcet, S. [1 ]
Cheng, J. [2 ]
Kumar, S. [3 ]
Tang, J. [3 ]
Blau, J. [2 ]
Zhao, Y. [2 ]
Zhang, W. [2 ]
Saha, B. [2 ]
Arunachalam, V. [3 ]
Heap, G. A. [2 ]
Thakker, P. [2 ]
Choudhury, A. [2 ]
机构：
[1] Rockefeller Univ, Lab Invest Dermatol, New York, NY USA
[2] Takeda Pharmaceut Int Co, Gastrointestinal & Inflammat Therapeut Unit, Cambridge, MA USA
[3] Takeda Pharmaceut Int Co, Gastrointestinal & Inflammat Therapeut Unit, San Diego, CA USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2024年 / 144卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
265
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [31] Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
    FitzGerald, Oliver
    Gladman, Dafna
    Mease, Philip J.
    Ritchlin, Christopher
    Smolen, Josef
    Gao, Lu
    Hu, Sarah
    Nowak, Miroslawa
    Banerjee, Subhashis
    Catlett, Ian M.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4229 - 4230
  • [32] INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL
    Gordon, Kenneth
    Papp, Kim
    Gooderham, Melinda
    Thaci, Diamant
    Foley, Peter
    Morita, Akimichi
    Kundu, Sudeep
    Kisa, Renata
    Napoli, Andrew
    Banerjee, Subhashis
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 907 - 908
  • [33] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast: subset analysis of patients with scalp psoriasis in the phase 3 POETYK PSO-1 and PSO-2 trials
    Foley, Peter
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 66 - 66
  • [34] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast: Subset Analysis of Patients With Scalp Psoriasis in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
    Thaci, Diamant
    Rich, Phoebe
    Sofen, Howard
    Merola, Joseph
    Strober, Bruce
    Morita, Akimichi
    Szepietowski, Jacek
    Colston, Elizabeth
    Throup, John
    Wang, Tao
    Banerjee, Subhashis
    Blauvelt, Andrew
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 25 - 25
  • [35] Cyclosporine has no clinically meaningful effect on pharmacokinetics (PK) of BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in healthy subjects
    Chimalakonda, A.
    Jones, J., III
    Dockens, R.
    Throup, J.
    Banerjee, S.
    Girgis, I.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S277 - S278
  • [36] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: efficacy analysis by prior treatment in the phase 3 POETYK PSO-1 and PSO-2 trials
    Foley, Peter
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 65 - 65
  • [37] An oral, selective TYK2 inhibitor, deucravacitinib, in patients with moderate-to-severe plaque psoriasis and baseline PASI ≤ 15 versus > 15
    Foley, P.
    Gooderham, M.
    Gordon, K.
    Thaci, D.
    Kundu, S.
    Kisa, R.
    Wei, Lan
    Banerjee, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 55 - 55
  • [38] Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (Tyk2) Inhibitor, in Patients With Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
    Mosca, Marta
    Arnaud, Laurent
    Askanase, Anca
    Hobar, Coburn
    Becker, Brandon
    Singhal, Shalabh
    Banerjee, Subhashis
    Pomponi, Samantha
    Choi, Jiyoon
    Coles, Adrian
    Touma, Zahi
    Keeling, Stephanie
    Strand, Vibeke
    JOURNAL OF RHEUMATOLOGY, 2024, 51 : 31 - 32
  • [39] Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
    Mosca, Marta
    Arnaud, Laurent
    Askanase, Anca
    Hobar, Coburn
    Becker, Brandon
    Singhal, Shalabh
    Banerjee, Subhashis
    Pomponi, Samantha
    Choi, Jiyoon
    Coles, Adrian
    Strand, Vibeke
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4611 - 4614
  • [40] Selective oral tyrosine kinase 2 (TYK2) inhibitor (BMS-986165) impact on quality of life (QOL) in patients with moderate to severe plaque psoriasis (PSO) in a phase 2 trial as assessed by the dermatology life quality index (DLQI)
    Thaci, D.
    Papp, K.
    Gordon, K.
    Morita, A.
    Gooderham, M.
    Foley, P.
    Kisa, R.
    Napoli, A.
    Kundu, S.
    Banerjee, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 71 - 72
12345